<p>在周四发布的一份研究报告中，瑞银集团的股票分析师将 Teva Pharmaceutical Industries（纽约证券交易所代码：TEVA - 获取免费报告）的目标股价从 36.00 美元上调至 42.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。瑞银集团的目标股价暗示该公司股价有 19.89% 的上涨潜力。</p>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p>其他几位研究分析师也最近对该股票发表了评论。Weiss Ratings 在 4 月 20 日的报告中重申了对 Teva Pharmaceutical Industries 股票的 “卖出（d-）” 评级。Jefferies Financial Group 在 1 月 6 日的报告中将 Teva Pharmaceutical Industries 的目标股价从 29.00 美元上调至 40.00 美元，并给予该股票 “买入” 评级。高盛集团在 2 月 9 日的报告中将 Teva Pharmaceutical Industries 的目标股价从 36.00 美元上调至 45.00 美元，并给予该股票 “买入” 评级。美国银行在 4 月 9 日的报告中将 Teva Pharmaceutical Industries 的目标股价从 38.00 美元上调至 42.00 美元，并给予该股票 “买入” 评级。最后，Scotiabank 在 1 月 29 日的报告中将 Teva Pharmaceutical Industries 的目标股价从 35.00 美元上调至 40.00 美元，并给予该股票 “行业表现优于大盘” 评级。九位投资分析师对该股票给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标股价为 41.00 美元。</p>
<p><strong>获取我们对 TEVA 的最新分析</strong></p>
<h2>Teva Pharmaceutical Industries 股票下跌 1.0%</h2>
<ul>
<li>Teva Pharma：为什么这家仿制药巨头现在是一个明智的买入选择</li>
</ul>
<p>周四，纽约证券交易所 TEVA 的股价下跌 0.35 美元，跌至 35.03 美元。该股票交易了 16,081,784 股，而其平均交易量为 8,323,869 股。该公司的速动比率为 0.80，流动比率为 1.04，债务与股本比率为 1.89。Teva Pharmaceutical Industries 的 52 周低点为 14.99 美元，52 周高点为 37.35 美元。该公司的市值为 402.8 亿美元，市盈率为 29.19，市盈增长比率为 2.75，贝塔值为 0.76。该公司的 50 日移动平均价格为 31.14 美元，200 日移动平均价格为 29.29 美元。</p>
<p>Teva Pharmaceutical Industries（纽约证券交易所代码：TEVA - 获取免费报告）最后一次发布季度财报是在 3 月 31 日，报告显示该季度每股收益为 0.53 美元。Teva Pharmaceutical Industries 的净利润率为 8.16%，股本回报率为 46.28%。该季度的收入为 39.8 亿美元。卖方分析师预计 Teva Pharmaceutical Industries 在当前财政年度将发布 2.6 美元的每股收益。</p>
<h2>内部人士下注</h2>
<ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
<p>在其他新闻中，内部人士 Mark Sabag 在 3 月 17 日的交易中出售了 62,102 股公司的股票。该股票以平均价格 30.14 美元出售，总价值为 1,871,754.28 美元。交易完成后，内部人士持有 224,940 股公司股票，价值约为 6,779,691.60 美元。这代表其持股比例下降了 21.64%。该销售在向 SEC 提交的文件中披露，文件可通过此链接访问。此外，首席执行官 Richard D. Francis 在 3 月 3 日的交易中出售了 442,935 股公司的股票。该股票以平均价格 32.36 美元出售，总交易额为 14,333,376.60 美元。交易完成后，首席执行官持有 642,099 股公司的股票，价值约为 20,778,323.64 美元。该交易使其持股比例下降了 40.82%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士已出售 920,901 股公司股票，价值 30,056,789 美元。当前公司内部人士持有 0.54% 的股票。</p>
<h2>Teva Pharmaceutical Industries 的机构交易</h2>
<p>一些大型投资者最近买入和卖出了该公司的股票。Global Retirement Partners LLC 在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 27.3%。Global Retirement Partners LLC 目前拥有 1,360 股公司股票，价值 42,000 美元，此前在该期间内购买了 292 股。Captrust Financial Advisors 在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 2.1%。Captrust Financial Advisors 目前拥有 14,715 股公司股票，价值 459,000 美元，此前在该期间内购买了 302 股。Banque Cantonale Vaudoise 在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 6.3%。Banque Cantonale Vaudoise 目前拥有 5,133 股公司股票，价值 160,000 美元，此前在该期间内购买了 306 股。Ethic Inc.在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 1.8%。Ethic Inc.目前拥有 18,127 股公司股票，价值 566,000 美元，此前在该期间内购买了 325 股。最后，Allworth Financial LP 在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 53.8%。Allworth Financial LP 目前拥有 941 股公司股票，价值 29,000 美元，此前在该期间内购买了 329 股。机构投资者和对冲基金持有该公司 54.05% 的股票。</p>
<h2>更多 Teva Pharmaceutical Industries 新闻</h2>
<p>以下是本周影响 Teva Pharmaceutical Industries 的主要新闻故事：</p>
<ul>
<li>积极情绪：第一季度业绩超出预期——Teva 报告第一季度收入约为 39.8 亿美元，每股收益为 0.53 美元（超出预期），主要受 Austedo、Ajovy 和 Uzedy 等品牌药物增长的推动，这支撑了最近的反弹。TEVA 第一季度收益超出预期</li>
<li>积极情绪：收购扩大增长管道——Teva 同意收购 Emalex Biosciences（交易金额约为 9 亿美元），该公司开发的 ecopipam 是一种即将提交新药申请的晚期 Tourette 综合症治疗药物，补充了 Teva 的神经科学业务，并支持短期和长期增长。Teva 收购 Emalex Biosciences</li>
<li>积极情绪：分析师提高目标价——Truist 将其目标价提高至 45 美元（买入），Piper Sandler 重申超配并将目标价上调至 42 美元，显示出分析师的持续信心，并为股票提供了上行支持。Truist 目标价上调 Piper Sandler 重申</li>
<li>积极情绪：机构兴趣和融资活动——报道指出，黑石集团的融资/兴趣显著，且期权活动（大量看涨期权购买）上升，表明买方对股价上涨的信心。黑石融资分析</li>
<li>中性情绪：指引更新但符合预期——Teva 重申 2026 财年每股收益指引（大约在 2.57 至 2.77 之间），与市场共识大致一致，留有执行空间以推动进一步上涨。第一季度业绩及指引</li>
<li>中性情绪：期权流动——报告显示异常大量的看涨期权购买，这可能会放大日内波动，但并不改变公司前景的基本面。</li>
<li>消极情绪：仿制药面临逆风——管理层指出仿制药表现疲软（包括 lenalidomide 仿制药收入下降），这是一个反复出现的压力点，抑制了盈利超预期的表现，意味着需要持续执行以维持增长。路透社：品牌药物推动业绩</li>
<li>消极情绪：短期获利回吐风险——在经历了多日约 10-12% 的上涨后，部分回调是正常的，因为交易者锁定收益；这种动态可能在短期内超过新的积极消息。</li>
</ul>
<h2>关于 Teva 制药工业</h2>
<p>(获取免费报告)</p>
<p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA 是一家以色列跨国制药公司，也是全球最大的仿制药制造商之一。公司的核心业务包括仿制药的开发、生产和营销，以及一系列专科品牌药物的组合。Teva 向全球市场提供成品剂型和活性药物成分（API），并在多个国家运营制造和研究设施。</p>
<p>Teva 的产品范围涵盖口服固体剂型、注射剂、吸入产品及其他剂型，涉及中枢神经系统疾病、呼吸系统、肿瘤、疼痛和传染病等治疗领域。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票超过 Teva 制药工业</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Teva 制药工业吗？</h2>
<p>在考虑 Teva 制药工业之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Teva 制药工业并不在名单上。</p>
<p>虽然 Teva 制药工业目前在分析师中获得中性买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

梯瓦制药

美国制药 ETF - iShares

<p>瑞士银行集团已将梯瓦制药（NYSE:TEVA）的目标价格从 36.00 美元上调至 42.00 美元，维持 “买入” 评级。这意味着相较于前一交易日的收盘价，潜在上涨幅度为 19.89%。其他分析师也给予了积极评级，普遍评级为 “适度买入”，平均目标价格为 41.00 美元。梯瓦的股票最近交易价格为 35.03 美元，下跌 1.0%。该公司在上个季度报告的收入为 39.8 亿美元，每股收益为 0.53 美元</p>

<p>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its price target hoisted by stock analysts at UBS Group from $36.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the stock. UBS Group's target price suggests a potential upside of 19.89% from the company's previous close.</p>
<div class="lb-trans"><p>在周四发布的一份研究报告中，瑞银集团的股票分析师将 Teva Pharmaceutical Industries（纽约证券交易所代码：TEVA - 获取免费报告）的目标股价从 36.00 美元上调至 42.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。瑞银集团的目标股价暗示该公司股价有 19.89% 的上涨潜力。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p>Several other research analysts have also recently commented on the stock. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, January 6th. The Goldman Sachs Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, February 9th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, April 9th. Finally, Scotiabank boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a &#34;sector outperform&#34; rating in a report on Thursday, January 29th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $41.00.</p>
<div class="lb-trans"><p>其他几位研究分析师也最近对该股票发表了评论。Weiss Ratings 在 4 月 20 日的报告中重申了对 Teva Pharmaceutical Industries 股票的 “卖出（d-）” 评级。Jefferies Financial Group 在 1 月 6 日的报告中将 Teva Pharmaceutical Industries 的目标股价从 29.00 美元上调至 40.00 美元，并给予该股票 “买入” 评级。高盛集团在 2 月 9 日的报告中将 Teva Pharmaceutical Industries 的目标股价从 36.00 美元上调至 45.00 美元，并给予该股票 “买入” 评级。美国银行在 4 月 9 日的报告中将 Teva Pharmaceutical Industries 的目标股价从 38.00 美元上调至 42.00 美元，并给予该股票 “买入” 评级。最后，Scotiabank 在 1 月 29 日的报告中将 Teva Pharmaceutical Industries 的目标股价从 35.00 美元上调至 40.00 美元，并给予该股票 “行业表现优于大盘” 评级。九位投资分析师对该股票给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标股价为 41.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on TEVA</strong></p>
<div class="lb-trans"><p><strong>获取我们对 TEVA 的最新分析</strong></p>
</div><h2>Teva Pharmaceutical Industries Stock Down 1.0%</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 股票下跌 1.0%</h2>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma：为什么这家仿制药巨头现在是一个明智的买入选择</li>
</ul>
</div><p>NYSE TEVA traded down $0.35 on Thursday, hitting $35.03. 16,081,784 shares of the stock were exchanged, compared to its average volume of 8,323,869. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a market cap of $40.28 billion, a PE ratio of 29.19, a PEG ratio of 2.75 and a beta of 0.76. The company has a 50-day moving average price of $31.14 and a 200-day moving average price of $29.29.</p>
<div class="lb-trans"><p>周四，纽约证券交易所 TEVA 的股价下跌 0.35 美元，跌至 35.03 美元。该股票交易了 16,081,784 股，而其平均交易量为 8,323,869 股。该公司的速动比率为 0.80，流动比率为 1.04，债务与股本比率为 1.89。Teva Pharmaceutical Industries 的 52 周低点为 14.99 美元，52 周高点为 37.35 美元。该公司的市值为 402.8 亿美元，市盈率为 29.19，市盈增长比率为 2.75，贝塔值为 0.76。该公司的 50 日移动平均价格为 31.14 美元，200 日移动平均价格为 29.29 美元。</p>
</div><p>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $3.98 billion during the quarter. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries（纽约证券交易所代码：TEVA - 获取免费报告）最后一次发布季度财报是在 3 月 31 日，报告显示该季度每股收益为 0.53 美元。Teva Pharmaceutical Industries 的净利润率为 8.16%，股本回报率为 46.28%。该季度的收入为 39.8 亿美元。卖方分析师预计 Teva Pharmaceutical Industries 在当前财政年度将发布 2.6 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
</div><p>In other news, insider Mark Sabag sold 62,102 shares of the company's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28. Following the completion of the transaction, the insider owned 224,940 shares in the company, valued at approximately $6,779,691.60. This represents a 21.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Richard D. Francis sold 442,935 shares of the company's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the completion of the transaction, the chief executive officer owned 642,099 shares of the company's stock, valued at approximately $20,778,323.64. The trade was a 40.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Mark Sabag 在 3 月 17 日的交易中出售了 62,102 股公司的股票。该股票以平均价格 30.14 美元出售，总价值为 1,871,754.28 美元。交易完成后，内部人士持有 224,940 股公司股票，价值约为 6,779,691.60 美元。这代表其持股比例下降了 21.64%。该销售在向 SEC 提交的文件中披露，文件可通过此链接访问。此外，首席执行官 Richard D. Francis 在 3 月 3 日的交易中出售了 442,935 股公司的股票。该股票以平均价格 32.36 美元出售，总交易额为 14,333,376.60 美元。交易完成后，首席执行官持有 642,099 股公司的股票，价值约为 20,778,323.64 美元。该交易使其持股比例下降了 40.82%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士已出售 920,901 股公司股票，价值 30,056,789 美元。当前公司内部人士持有 0.54% 的股票。</p>
</div><h2>Institutional Trading of Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 的机构交易</h2>
</div><p>A number of large investors have recently bought and sold shares of the business. Global Retirement Partners LLC boosted its stake in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock worth $42,000 after purchasing an additional 292 shares during the period. Captrust Financial Advisors boosted its stake in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company's stock worth $459,000 after purchasing an additional 302 shares during the period. Banque Cantonale Vaudoise boosted its stake in Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company's stock worth $160,000 after purchasing an additional 306 shares during the period. Ethic Inc. boosted its stake in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company's stock worth $566,000 after purchasing an additional 325 shares during the period. Finally, Allworth Financial LP boosted its stake in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company's stock worth $29,000 after purchasing an additional 329 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近买入和卖出了该公司的股票。Global Retirement Partners LLC 在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 27.3%。Global Retirement Partners LLC 目前拥有 1,360 股公司股票，价值 42,000 美元，此前在该期间内购买了 292 股。Captrust Financial Advisors 在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 2.1%。Captrust Financial Advisors 目前拥有 14,715 股公司股票，价值 459,000 美元，此前在该期间内购买了 302 股。Banque Cantonale Vaudoise 在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 6.3%。Banque Cantonale Vaudoise 目前拥有 5,133 股公司股票，价值 160,000 美元，此前在该期间内购买了 306 股。Ethic Inc.在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 1.8%。Ethic Inc.目前拥有 18,127 股公司股票，价值 566,000 美元，此前在该期间内购买了 325 股。最后，Allworth Financial LP 在第四季度将其在 Teva Pharmaceutical Industries 的股份增加了 53.8%。Allworth Financial LP 目前拥有 941 股公司股票，价值 29,000 美元，此前在该期间内购买了 329 股。机构投资者和对冲基金持有该公司 54.05% 的股票。</p>
</div><h2>More Teva Pharmaceutical Industries News</h2>
<div class="lb-trans"><h2>更多 Teva Pharmaceutical Industries 新闻</h2>
</div><p>Here are the key news stories impacting Teva Pharmaceutical Industries this week:</p>
<div class="lb-trans"><p>以下是本周影响 Teva Pharmaceutical Industries 的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Q1 results beat expectations — Teva reported Q1 revenue of ~$3.98B and EPS of $0.53 (beat), driven by growth in branded drugs including Austedo, Ajovy and Uzedy, which underpinned the recent rally. TEVA Q1 Earnings Top Estimates</li>
<li>Positive Sentiment: Acquisition expands growth pipeline — Teva agreed to acquire Emalex Biosciences (deal reported up to ~$900M) for ecopipam, a late‑stage, NDA‑ready Tourette therapy that complements Teva’s neuroscience franchise and supports near‑ and long‑term growth. Teva to Acquire Emalex Biosciences</li>
<li>Positive Sentiment: Analysts raising targets — Truist raised its price target to $45 (buy) and Piper Sandler reaffirmed overweight and lifted its target to $42, signaling continued analyst confidence and providing upside support for the stock. Truist price target raisePiper Sandler reaffirmation</li>
<li>Positive Sentiment: Institutional interest and financing activity — Coverage pieces flagged a meaningful financing/interest from Blackstone and elevated options activity (large call buying), suggesting buy‑side conviction behind the move higher. Blackstone financing analysis</li>
<li>Neutral Sentiment: Guidance updated but in line — Teva reiterated FY‑2026 EPS guidance (roughly 2.57–2.77), broadly consistent with consensus, leaving room for execution to drive further upside. Q1 results &amp; guidance</li>
<li>Neutral Sentiment: Options flow — Unusually large call buying was reported, which can amplify intraday moves but is not a fundamental change to the company’s outlook.</li>
<li>Negative Sentiment: Generics headwinds remain — Management flagged weaker generics performance (including lower lenalidomide generic revenue), a recurring pressure point that tempers the earnings beat and means continued execution is needed to sustain growth. Reuters: branded drugs drive results</li>
<li>Negative Sentiment: Short‑term profit‑taking risk — After a multi‑day ~10–12% run, some pullback is normal as traders book gains; that dynamic can outweigh fresh positive headlines in the near term.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度业绩超出预期——Teva 报告第一季度收入约为 39.8 亿美元，每股收益为 0.53 美元（超出预期），主要受 Austedo、Ajovy 和 Uzedy 等品牌药物增长的推动，这支撑了最近的反弹。TEVA 第一季度收益超出预期</li>
<li>积极情绪：收购扩大增长管道——Teva 同意收购 Emalex Biosciences（交易金额约为 9 亿美元），该公司开发的 ecopipam 是一种即将提交新药申请的晚期 Tourette 综合症治疗药物，补充了 Teva 的神经科学业务，并支持短期和长期增长。Teva 收购 Emalex Biosciences</li>
<li>积极情绪：分析师提高目标价——Truist 将其目标价提高至 45 美元（买入），Piper Sandler 重申超配并将目标价上调至 42 美元，显示出分析师的持续信心，并为股票提供了上行支持。Truist 目标价上调 Piper Sandler 重申</li>
<li>积极情绪：机构兴趣和融资活动——报道指出，黑石集团的融资/兴趣显著，且期权活动（大量看涨期权购买）上升，表明买方对股价上涨的信心。黑石融资分析</li>
<li>中性情绪：指引更新但符合预期——Teva 重申 2026 财年每股收益指引（大约在 2.57 至 2.77 之间），与市场共识大致一致，留有执行空间以推动进一步上涨。第一季度业绩及指引</li>
<li>中性情绪：期权流动——报告显示异常大量的看涨期权购买，这可能会放大日内波动，但并不改变公司前景的基本面。</li>
<li>消极情绪：仿制药面临逆风——管理层指出仿制药表现疲软（包括 lenalidomide 仿制药收入下降），这是一个反复出现的压力点，抑制了盈利超预期的表现，意味着需要持续执行以维持增长。路透社：品牌药物推动业绩</li>
<li>消极情绪：短期获利回吐风险——在经历了多日约 10-12% 的上涨后，部分回调是正常的，因为交易者锁定收益；这种动态可能在短期内超过新的积极消息。</li>
</ul>
</div><h2>About Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>关于 Teva 制药工业</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA 是一家以色列跨国制药公司，也是全球最大的仿制药制造商之一。公司的核心业务包括仿制药的开发、生产和营销，以及一系列专科品牌药物的组合。Teva 向全球市场提供成品剂型和活性药物成分（API），并在多个国家运营制造和研究设施。</p>
</div><p>Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.</p>
<div class="lb-trans"><p>Teva 的产品范围涵盖口服固体剂型、注射剂、吸入产品及其他剂型，涉及中枢神经系统疾病、呼吸系统、肿瘤、疼痛和传染病等治疗领域。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Teva 制药工业</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=TEVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Teva 制药工业吗？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Teva 制药工业之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Teva 制药工业并不在名单上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Teva 制药工业目前在分析师中获得中性买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

UBS Group Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Market Beat

瑞银集团

Jefferies Financial

高盛

美国银行

Bank of Nova Scottia

GS Hldg R

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

瑞银集团对梯瓦制药（NYSE:TEVA）的股票价格发布了乐观的预测